Drug Database
Back to search

Iceland· IS-EU/1/20/1492/001

Tecartus

A brexucabtagene autoleucel product containing brexucabtagenum autoleucelum inn, registered in Iceland by Kite Pharma EU B.V.. The same ATC class is registered in 13 of our 19 countries.

ATC L01XL06

Checked against Icelandic Medicines Agency (Iceland) on

Informational only — not a medical device.

SOURCE REGISTER · ISIcelandic Medicines Agency (Iceland)normalisedTecartusATCL01XL06REGISTER NO.IS-EU/1/20/1492/001PACKS LISTED0CHECKEDSeptember 29, 2026
Compare price across countriesPer daily dose · free accountAsk the assistant about brexucabtagenum autoleucelum innAnswers with sources · free accountCheck interactionsSeverity free · mechanism on Growth

Where it is registered

Brexucabtagene autoleucel is registered in 13 of 19 countries.

Countries holding a registration under ATC L01XL06 (brexucabtagene autoleucel), each read from that country’s own register.

  • This record: Iceland, from Icelandic Medicines Agency (Iceland)
  • 8 of them publish a price we can compare per daily dose
Search brexucabtagene autoleucel products by name

Brexucabtagene autoleucel · ATC L01XL06

13 / 19 countries

  • Belgiumprice
  • Canada
  • Czechiaprice
  • Denmark
  • Finlandprice
  • Icelandprice
  • Ireland
  • Netherlands
  • Norwayprice
  • Polandprice
  • Switzerlandprice
  • United Kingdom
  • United Statesprice
Blue: a registration under this ATC code. The ringed marker is this record’s country. Markets marked price publish a price we can compare per daily dose.

The record

At a glance

Icelandic Medicines Agency (Iceland)
Active substance
Brexucabtagenum autoleucelum INN
Manufacturer
Kite Pharma EU B.V.
Country
Iceland (IS)
ATC code
L01XL06
ATC class
Brexucabtagene autoleucel
Reimbursed
Not published by this register
Source register
Icelandic Medicines Agency (Iceland)
Last checked
September 29, 2026

Packs & prices · 0

No packs listed by the register for this record.

Regulatory notes

No shortage, Orange Book or US label notes for this record.

Interactions

82 interactions on record for brexucabtagene autoleucel.

Graded by severity as the source publishes them — 51 severe. Severity grades are free for everyone; mechanism and management come with Growth.

  • Severity for every pair — free, no plan needed
  • The source, licence and sync date on every record
  • Mechanism and what to do for each pair — Growth plan
Check brexucabtagene autoleucel against other medicinesHow interaction checks work

Brexucabtagene autoleucel · interactions on record

82 records

  • 51 severe
  • 31 moderate

Most severe, free to view

  • PrednisoloneA07EA01severe
  • HydrocortisoneA07EA02severe
  • PrednisoneA07EA03severe
  • BetamethasoneA07EA04severe
  • Interaction severity from DDInter 2.0 (Xiong G. et al., Nucleic Acids Res.), licensed CC BY-NC 4.0 — free for non-commercial use only; not covered by the Drug Database commercial licence.
Mechanism and what to do, in the interaction check
Source: DDInter 2.0 · synced 29 Sept 2026. Grades as the source publishes them.

Same medicine, other countries

Brexucabtagene autoleucel in 11 other countries

What each register calls a product with the same active substance — salts and hydrates count as the same.

All brexucabtagene autoleucel products

Authorised across Europe · EMA

The same active substance is authorised in 2 EEA countries. Names it is sold under:

  • Liechtenstein · Tecartus
  • Norway · Tecartus

Source: European Medicines Agency, Article 57 product data.

Sourced from a public register and reproduced with attribution. Drug Database is not affiliated with, endorsed by, or a partner of Icelandic Medicines Agency (Iceland). This is an informational data service and not a medical device — verify against the official source of record before any clinical decision.

For developers

The same record over the API, and the raw payload
GET /v1/drugs/d430fcff-a8c0-496e-91bf-d9a73d03ff43
GET /v1/drugs/d430fcff-a8c0-496e-91bf-d9a73d03ff43?format=fhir

Every response carries last_synced_at, so freshness is a field rather than a promise. Below is exactly what the ingestion wrote, before any presentation — the same JSON the API returns under payload.

{
  "form": "Innrennslislyf, ördreifa",
  "source": "lyfjastofnun",
  "atc_raw": "L01XL06",
  "marketed": true,
  "strength": "0,4 - 2,0 x 10^8 frumur",
  "ma_number": "EU/1/20/1492/001",
  "substance": "Brexucabtagenum autoleucelum INN",
  "other_info": "Markaðssetning á Íslandi er háð því að Lyfjastofnun hafi staðfest að sérstök skilyrði er varða öryggi og verkun við notkun lyfsins séu uppfyllt.",
  "legal_status": "(R) Lyfseðilsskylt\r\n(H) Sjúkrahúsmerkt",
  "ma_issued_serial": "44179"
}
API referenceMCP serverPlans

See everything about brexucabtagene autoleucel.

This page is the registration. A free account adds the label text as the regulator wrote it, what it costs per daily dose across the markets that publish a price, a feed of what changes in the registers, and an assistant that answers with its sources. Interaction severity is free; mechanism and management are on the Growth plan. No card, nothing to install.

Try it freeOpen in the console